Cargando…

Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?

Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with metastatic urothelial cancer (mUC). If these agents were first used in monotherapy after failure of platinum-based chemotherapy, new strategies have been evaluated in the last years, including association of...

Descripción completa

Detalles Bibliográficos
Autores principales: Houssiau, Hélène, Seront, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917314/
https://www.ncbi.nlm.nih.gov/pubmed/35278793
http://dx.doi.org/10.1016/j.tranon.2022.101387